News
Research Spotlight: Po Hien Ear, PhD
Dr. Po Hien Ear’s research involves growing NET spheroid clusters in large enough numbers to be used to screen the potential anti-tumor properties of hundreds of therapeutic compounds.
Clinical Trial of Belzutifan in Pancreatic NETs and Pheo/Para
A phase II clinical trial has opened to investigate the safety and effectiveness of the drug belzutifan for pancreatic neuroendocrine tumors (pNETs) and pheochromocytoma/paraganglioma (PPGL).
Etay Ziv, MD, PhD, Studying NET Progression in NETRF-Funded AACR Research Project
Etay Ziv, MD, PhD, an interventional radiologist at Memorial Sloan Kettering Cancer Center in New York, leads a translational research study, funded by NETRF through the American Association for Cancer Research, that aims to understand the process of how pancreatic NETs progress from low grade to higher, more aggressive grade tumors.
Join the eNET Study!
Doctors at University of California San Francisco (UCSF) are conducting the first-of-its-kind e-NET study to learn about symptoms and quality of life for patients with neuroendocrine cancer. This is your chance to become a citizen scientist and help the researchers learn more about NETs.
Judy’s Walk for NET Research
A Family Takes Steps to Honor the Memory of their Loved One Judith Jones loved Nantucket. From the first time she visited the island off
An Outpouring of Love for a NET Patient with Sass
Cyclebar Hilltop riders rally to support one of their instructors in her NET journey, and raise funds for NETRF research.
Ali Azhdarinia, PhD, Recognized by AACR for NETRF-Funded Research
The American Association for Cancer Research recently recognized the NETRF-funded research of Ali Azhdarinia, PhD, of the University of Texas Health Science Center at Houston. Dr. Azhdarinia is investigating image-guided precision medicine to treat NETs in the gastrointestinal tract and pancreas that are resistant to chemotherapy.
NETRF Welcomes Two New Members to its Board of Scientific Advisors
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to welcome Dr. Matthew H. Kulke and Dr. Daniel M. Halperin to its Board of Scientific Advisors (BOSA), a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the understanding, diagnosis, and treatment of neuroendocrine cancer. Although these renowned physicians may be new to the BOSA, they are not new to NETs or NETRF. In fact, they are both recognized as leading experts worldwide for their care of NET patients and research.
Net One for NET Research – In Memory of Brandon Raabe
If you could ask Brandon Raabe what a perfect day would look like, he would probably describe a Sunday afternoon in a brewery surrounded by
Improving Global Access to Net Treatments and Care
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to collaborate with the International Neuroendocrine Cancer Alliance (INCA) to share the results from the Survey of